Latest Market Entry News

Wellnex Life Limited reports a robust 46% revenue increase and successful AIM listing, setting the stage for UK and European expansion.

Orthocell has secured regulatory approval to sell its nerve repair product Remplir™ in Hong Kong well ahead of schedule, expanding its footprint across key global markets. This milestone complements recent clearances in the US, Canada, and Asia, positioning the company for significant growth in a multi-billion-dollar market.

Wide Open Agriculture secures $2.6 million via placement and plans a $500,000 Share Purchase Plan to fast-track its expansion into China and boost global sales of its lupin protein products.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.

CLINUVEL Pharmaceuticals has completed recruitment for its Phase III trial of SCENESSE® in vitiligo patients with darker skin types, setting the stage for first results in late 2026. Early clinical observations suggest promising repigmentation outcomes.

Eden Innovations has secured its inaugural order from Holcim Mexico for EdenCretePz7, marking a strategic expansion into a major new market and extending its footprint within the global Holcim Group.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Hazer Group has entered a binding six-year strategic alliance with global engineering leader KBR to exclusively market and license its methane pyrolysis technology, targeting the ammonia and methanol sectors. This partnership aims to accelerate commercialisation, expand global reach, and materially de-risk Hazer’s business plan.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Wide Open Agriculture Limited has clarified that its recently signed offtake and distribution agreement with Univar Solutions China carries no immediate financial impact, outlining a phased market entry and sales timeline.

DUG Technology reported a 23% surge in software revenue and a 15% rise in EBITDA for FY25-Q3, underpinned by strong services order growth and strategic expansion into Brazil.